Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Core Insights - Vistin Pharma ASA reported a revenue increase in Q3 2025, reaching MNOK 109, up from MNOK 106 in Q3 2024, driven by a 10% higher sales volume [1] - Year-to-date revenue for 2025 is MNOK 342, an 8% increase from MNOK 316 in the same period last year [1] - The company's EBITDA for Q3 2025 was MNOK 28, slightly down from MNOK 29 in Q3 2024, impacted by lower global metformin prices [1] - Year-to-date EBITDA for 2025 stands at MNOK 89, a 16% increase from MNOK 77 in YTD 2024 [1] - Net profit for Q3 2025 was MNOK 18.5, compared to MNOK 16.6 in the previous year [2] - The company achieved an all-time high production volume of 1,600 MT of metformin in the quarter [2] Financial Performance - Q3 2025 revenue: MNOK 109, up 2.8% from Q3 2024 [1] - YTD 2025 revenue: MNOK 342, an 8% increase from YTD 2024 [1] - Q3 2025 EBITDA: MNOK 28, down from MNOK 29 in Q3 2024 [1] - YTD 2025 EBITDA: MNOK 89, up 16% from YTD 2024 [1] - Q3 2025 net profit: MNOK 18.5, compared to MNOK 16.6 in Q3 2024 [2] Production and Operations - All-time high production volume of metformin: 1,600 MT in Q3 2025 [2]